Cancer patients gain insurance coverage for genetic testing under Medicare, Medicaid, CHIP.

What it does

This bill requires Medicare, Medicaid, and CHIP to cover advanced cancer diagnostic tests (genetic sequencing, microarray analysis, and similar tests) that identify mutations in cancer patients. Tests are covered once at initial diagnosis, once at recurrence, and as needed for treatment planning. Medicare beneficiaries pay 20% coinsurance; Medicaid and CHIP cover the tests with no cost-sharing. The bill also funds a public education program on genetic testing for doctors and patients.

Why we flagged it

The bill's core mechanism is a straightforward expansion of insurance coverage for genetic and molecular cancer tests under three federal health programs. It is a public health measure, not a tax provision, deregulation, or narrow carve-out.

What the text implies

• The bill defines 'cancer diagnostic and laboratory tests' to include next-generation sequencing and microarray analysis, but does not specify which tests qualify or set reimbursement rates — implementation will depend on CMS rulemaking, creating potential for coverage gaps or delays.
• Medicaid coverage begins January 1, 2027, but CHIP coverage begins January 1, 2025 — a two-year gap may create disparities in access for low-income children depending on state implementation.
• The bill does not address prior authorization, network restrictions, or whether tests must be ordered by oncologists only — coverage may be narrower in practice than the statutory language suggests.
• Reimbursement is tied to 'clinical diagnostic laboratory test' rates under section 1834A, which may be lower than the actual cost of advanced sequencing, potentially limiting lab participation or test availability.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Cancer patients gain access to advanced diagnostic tests with insurance coverage, reducing financial barriers to precision medicine. Physicians gain tools to detect mutations and tailor treatment. The bill expands a public health benefit without restricting existing rights or protections.

Who stands to gain

• clinical laboratories performing genetic sequencing and microarray analysis
• genetic testing companies
• oncology practices and cancer centers

Named in the bill

Medicare, Medicaid, CHIP (Children's Health Insurance Program), Social Security Act, Centers for Medicare & Medicaid Services (CMS), National Human Genome Research Institute, clinical laboratories, genetic counselors

Where it stands

1 cosponsor: 1 Democrats.

• Feb 26, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Feb 26, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.